Search for a trial

A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia

Primary• To determine in patients with higher-risk myelodysplastic syndrome (HR MDS), chronic myelomonocytic leukemia (CMML), and low-blast acute myelogenous leukemia (AML) whether the combination of pevonedistat and azacitidine improves event-free…

A phase I/II trial towards the safety and efficacy of preemptive vaccination with PD-L silenced, minor histocompatibility antigen UTA2-1 peptide-loaded Dendritic Cells after Allogeneic Stem Cell Transplantation

- To evaluate the toxicity and feasibility of a preemptive minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DCvaccination.- To evaluate the effect of a minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC vaccination on the immunestatus of…

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in
Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

To assess and compare efficacy (complete response [CR] rate and overall survival [OS]) between SGI-110 and TC in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.

Cognitive Bias Modification: Exploring the effects of a computer-based cognitive bias training in patients with acute myeloid leukemia at risk for depression and anxiety symptoms -(HemaCogTrain)

The purpose of our exploratory study is to test the effect of a computer-based cognitive behavioural intervention (called Cognitive Bias Modification, CBM) on affective symptoms in patients with AML during their stay at the hospital.

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT).

Primary Objective:Efficacy:· Evaluate the efficacy of subcutaneous (sc) azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in the defined study population.Secondary Objectives:Safety:· Assess the safety and…

Long-term follow-up of patients previously treated with autologous T cells genetically modified with retroviral vectors.

Primary Objective:- Long-term safetySecondary Objective:- Survival- Clinical efficacy of AUTO CAR T cell therapy in patients enrolled prior to disease progression- Chimeric antigen receptor (CAR) transgene persistence- Replication competent…

A Phase 1 Trial to Assess the Mass Balance and Pharmacokinetics of 14C-Guadecitabine in Subjects with AML, MDS, or Solid Tumors

This study will provide an estimate of basic PK parameters for guadecitabine, an assessment of the routes and rates of elimination of radioactivity, and identification of metabolites and metabolic pathways.

A phase I, open label, multicenter, dose-escalation study of oral HDM201 in adult patients with advanced solid and hematological tumors characterized by wild-type TP53

Primary objective To determine the MTD and/or to identify the RDE of HDM201 in one or more of the pre-defined regimensSecondary objectives * To characterize the safety and tolerability of HDM201* To characterize the pharmacokinetic (PK) properties…